1. Pfizer Inc. Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19. Available from:https://www.pfizer.com/news/press-release/press-release-detail/pfizers-paxlovidtm-receives-fda-approval-adult-patients. Accessed June 05, 2023.
2. Oral Nirmatrelvir for high-risk, nonhospitalized adults with covid-19;Hammond;N Engl J Med,2022
3. Nirmatrelvir plus Ritonavir for early COVID-19 in a large U.S. Health system: a population-based cohort study;Dryden-Peterson;Ann Intern Med,2023
4. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB;Imai;N Engl J Med,2023
5. US Department of Health & Human Services, Administration for strategic preparedness and response. COVID-19 therapeutics thresholds, orders, and replenishment by jurisdiction. Available from: https://aspr.hhs.gov/COVID-19/Therapeutics/orders/Pages/default.aspx. Accessed September 20, 2022.